TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23945571
Drug: IM penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IM penicillin and gentamicin OD for 2 days, followed by oral amoxicillin twice daily for 5 days
Study: 23945571
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of once‐daily (OD) intramuscular (IM) procaine penicillin and gentamicin
Study: 21685374
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg daily plus Pegylated IFN-α2b 50 μg weekly
Study: 21685374
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg daily monotherapy
Study: 18436182
Drug: Sublingual hyoscyamine
Normalized name: hyoscyamine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual hyoscyamine spray (0.25 mg)
Study: 16494628
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (150 mg)
Study: 16494628
Drug: Testosterone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (250 mg)
Study: 12931748
Drug: Topical antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antihistamine (4 times daily)
Study: 12931748
Drug: Topical lodoxamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lodoxamide (4 times daily)
Study: 12931748
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine 0.5% (4 times daily)
Study: 12931748
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine compared to topical corticosteroids
Study: 10980901
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of ACE inhibitors
Study: 10980901
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II type I receptor blockade (ARB)
Study: 10980901
Drug: Higher-than-standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-than-standard doses of ACE inhibitors
Study: 9183781
Drug: Packy &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Packy & Marlon (treatment group)
Study: 25016274
Drug: Manual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy (Maitland joint mobilization)
Study: 25016274
Drug: Electrophysical Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrophysical Agents (TENS and cold pack)
Study: 20719727
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg daily for at least 1 month preoperatively
Study: 20719727
Drug: No atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No atorvastatin preoperatively
Study: 12552338
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (lysine +/- arginine)
Study: 8609343
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor-alpha levels in patients in functional classes I to III (1.95 +/- 0.54, 2.63 +/- 0.48, 6.4 +/- 1.9 pg/ml)
Study: 8609343
Drug: Interleukin-6 levels
Normalized name: interleukin-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-6 levels in patients in functional classes I to III (3.3 +/- 0.55, 6.2 +/- 1.1, 5.22 +/- 0.9 pg/ml)
Study: 18725484
Drug: Metoprolol (beta(1)-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (beta(1)-selective adrenergic blocker)
Study: 8859726
Drug: recombinant interleukin‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant interleukin‐2 (rIL‐2) at doses of 3.0, 12.0, and 48.0 x 10(6) IU/m(2) i.v. three times weekly (TIW) and recombinant human IL‐4 (rHuIL‐4) at doses of 40, 120, and 400 mu g/m(2) s.c. TIW
Study: 1517910
Drug: Cow milk-specific
Normalized name: Cow milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow milk-specific antibody responses
Study: 1517910
Drug: IgE-specific antibody
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgE-specific antibody concentrations and IgE/IgG-specific ratios for both milk proteins
Study: 1517910
Drug: IgG1- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG1- and IgG4-specific antibody to casein
Study: 21864417
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil (1 g/d)
Study: 21864417
Drug: EPA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-rich fish oil (1 g/d)
Study: 17823963
Drug: 480 mg
Normalized name: magaldrate 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg caffeine
Study: 17445520
Drug: Caffeine-free (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-free (placebo) solution
Study: 8936618
Drug: Gargling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gargling with a remote foot pedal-operated gargling apparatus 3 times during daily work over a 3-month period
Study: 26873871
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of Exenatide and Metformin (5 μg Exenatide + 0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide + 0.5 g MET twice daily for 24 weeks)
Study: 20508383
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose (FPG) value of 95-99 mg/dL
Study: 20508383
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose (FPG) value of 100-104 mg/dL
Study: 20508383
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose (FPG) value of 105-109 mg/dL
Study: 20508383
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose (FPG) value of 110-114 mg/dL
Study: 20508383
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose (FPG) value of 115-119 mg/dL
Study: 20508383
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose (FPG) value of 120-125 mg/dL
Study: 20508383
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose (FPG) value of 102 mg/dL
Study: 18353592
Drug: 4-hydroxy-anethole trithione
Normalized name: anethole trithione
DrugBank: Anethole trithione (DB13853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-hydroxy-anethole trithione (ATX) tablets produced by different companies
Study: 18353592
Drug: ATX tablets
Normalized name: ATX-01
DrugBank: ATX-01 (DB18141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATX tablets
Study: 17117566
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus western medicine (treatment group)
Study: 17117566
Drug: Simple western
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple western medicine (control group)
Study: 12842239
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet agent treatment
Study: 10923774
Drug: Ondansetron 24
Normalized name: ondansetron 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 24 mg
Study: 4032389
Drug: Lavage with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavage with 800 ml of saline plus 2 gm of cefamandole nafate
Study: 4032389
Drug: Lavage with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavage with 800 ml of saline alone
Study: 27787363
Drug: Alfentanil 5
Normalized name: alfentanil 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 5 μg/kg immediately before propofol administration
Study: 27787363
Drug: Alfentanil 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 2.5 μg/kg immediately before propofol administration
Study: 27787363
Drug: Alfentanil 5
Normalized name: alfentanil 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 5 μg/kg 2 minutes before propofol administration
Study: 27787363
Drug: Propofol administration
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administration alone (control group 5)
Study: 24867835
Drug: Botox treatment
Normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox treatment
Study: 18173402
Drug: Natural bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural bone mineral in combination with a collagen membrane (NBM+CM)
Study: 3521842
Drug: Intraperitoneal (IP)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (IP) 5-Fluorouracil (5-FU) chemotherapy
Study: 3521842
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) 5-Fluorouracil (5-FU) chemotherapy
Study: 3521842
Drug: Pelvic radiation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic radiation therapy
Study: 3521842
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil (5-FU) chemotherapy (both IP and IV)
Study: 20233669
Drug: ReNu MultiPlus
Normalized name: ReNu MultiPlus No-Rub Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReNu MultiPlus Multipurpose Solution with PureVision silicon hydrogel contact lens
Study: 18519845
Drug: Lisinopril (angiotensin-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (angiotensin-converting enzyme blocker)
Study: 18519845
Drug: Both medications
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both medications (Lisinopril and Atenolol)
Study: 12499819
Drug: Concurrent chemo‐radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemo‐radiation therapy (external beam radiotherapy 4,500 cGy over 5 weeks and intrahepatic arterial 5‐FU infusion 500 mg on days 1-5 and 30-35)
Study: 12499819
Drug: Intrahepatic arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrahepatic arterial cisplatin infusion (80 mg/m(2))
Study: 10417455
Drug: Antiplatelet drug
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet drug therapy
Study: 7739736
Drug: Hib vaccine
Normalized name: ActHIB vaccine 0.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib vaccine (administered at 3, 4, 5, and 11 months)
Study: 6996929
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g magnesium dithiosalicylate daily
Study: 6996929
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g aspirin daily
Study: 29089356
Drug: Spironolactone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (40 mg orally, twice daily) for 2 months
Study: 25040433
Drug: Tablet-based interactive
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based interactive distraction (TBID)
Study: 25040433
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg·kg(‐1); 20 mg max)
Study: 11136260
Drug: Inhaled triamcinolone
Normalized name: triamcinolone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled triamcinolone acetonide 600 microg twice daily
Study: 29735484
Drug: Inclisiran 300
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 300 mg 2-dose regimen (100 mg on day 1 and 300 mg on day 90)
Study: 29735484
Drug: Inclisiran 300
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 300 mg 2-dose regimen
Study: 23044303
Drug: Metformin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (n = 41)
Study: 23044303
Drug: Antioxidant treatment
Normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant treatment using lipoic acid
Study: 20492627
Drug: Shampoo treatment
Normalized name: Head & Shoulders Damage Treatment Shampoo Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shampoo treatment with ultrapure soft water (UPSW)
Study: 20492627
Drug: Shampoo treatment
Normalized name: Head & Shoulders Damage Treatment Shampoo Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shampoo treatment with tap water
Study: 11921320
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus hormonal therapy
Study: 9696733
Drug: Primaquine, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine, 30 mg/d for 15 weeks
Study: 1115011
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg of pyridoxine hydrochloride
Study: 1115011
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg of pyridoxine hydrochloride
Study: 1115011
Drug: 20.0 mg
Normalized name: RUXOLITINIB 20.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20.0 mg of pyridoxine hydrochloride
Study: 20176498
Drug: High-dose GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GH group (0.012 mg/kg/day)
Study: 20176498
Drug: Low-dose GH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GH group (0.006 mg/kg/day)
Study: 18803944
Drug: Oral D-chiro-inositol
Normalized name: chiro-inositol, (+)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral D-chiro-inositol (DCI) supplementation
Study: 12368782
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine infusion for 48 hours
Study: 12368782
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion for 48 hours (placebo)
Study: 10211628
Drug: Oral 5-aminolevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-aminolevulinic acid (ALA) administration to normal volunteers
Study: 10211628
Drug: Oral 5-aminolevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-aminolevulinic acid (ALA) administration
Study: 8585739
Drug: Amoxicillin-clavulanate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (10 days)
Study: 6123836
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg every 8 h for three days postoperatively)
Study: 31447077
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) + Abiraterone acetate and prednisolone (AAP)
Study: 17606474
Drug: Dietary 5-HT
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary 5-HT stimulation (tryptophan-rich alpha-lactalbumin, 4.8 g/100 g TRP)
Study: 17606474
Drug: Placebo protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo protein (1.4 g/100 g TRP)
Study: 25728808
Drug: Vancomycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (125 mg four times a day for 3 days, followed by 125-500 mg/day every 2-3 days for at least 3 weeks)
Study: 23380105
Drug: Intravenous valproic
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous valproic acid (iVPA) 400 mg
Study: 23380105
Drug: Intramuscular metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular metoclopramide + subcutaneous sumatriptan (10 mg + 6 mg)
Study: 19391535
Drug: Medication (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (oral administration of Vit E and Vit C)
Study: 16805717
Drug: Antidiabetic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic treatments (e.g., thiazolidinediones)
Study: 6383741
Drug: Lorcainide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcainide (100 mg twice daily or three times daily)
Study: 6383741
Drug: Quinidine gluconate
Normalized name: Quinidine Gluconate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine gluconate (324 mg three times daily)
Study: 21704964
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab monthly for 12 months
Study: 29575941
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab monthly for 4 months followed by pro re nata injections
Study: 29575941
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg ranibizumab monthly for 12 months
Study: 29575941
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg ranibizumab monthly for 4 months followed by pro re nata injections
Study: 29575941
Drug: High-dose ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ranibizumab
Study: 29575941
Drug: Conventional-dose ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conventional-dose ranibizumab
Study: 19834507
Drug: Topical Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cyclosporine A (CsA) and artificial tear-drop treatment
Study: 19834507
Drug: Topical artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical artificial tear-drop treatment
Study: 12970812
Drug: Verbal or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal or written informed consent prior to administration of Rh immune globulin
Study: 9658375
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A/hepatitis B vaccine
Study: 29331328
Drug: High-Flow Nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Nasal Cannula (HFNC) oxygen therapy
Study: 28298878
Drug: Conventional Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Oxygen Therapy (COG)
Study: 27765582
Drug: TXA Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA Dose I ‐ 1 g bolus followed by 1 g infusion over 8 h
Study: 27765582
Drug: TXA Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA Dose II ‐ 1 g bolus followed by 10 mg/kg/hr until the end of surgery
Study: 24311515
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g EPA-rich lipid for 12 weeks
Study: 18589448
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (n = 76)
Study: 10491451
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fluticasone propionate (2000 microg/day, FP2000)
Study: 10491451
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (30 mg/day)
Study: 10491451
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose fluticasone propionate (500 microg/day, FP500)
Study: 8367920
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate (3.6 mg s.c. once every four weeks) and flutamide (250 mg three times daily)
Study: 31578169
Drug: Pirfenidone 2403
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone 2403 mg daily
Study: 26810904
Drug: Continuous sciatic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sciatic block (continuous infusion)
Study: 25363150
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments including rituximab
Study: 28459603
Drug: Open-loop (OL)
Normalized name: limonen-10-ol, (+)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-loop (OL) conventional pump therapy (OL1/OL2)
Study: 23786436
Drug: Trust in
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trust in racial equity of treatment
Study: 18678610
Drug: Technosphere insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Technosphere insulin
Study: 14557959
Drug: Azithromycin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1000 mg, single oral dose)
Study: 14557959
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg, single oral dose)
Study: 3710012
Drug: Saline (154
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (154 mmol/l)
Study: 27916047
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg atorvastatin (standard group)
Study: 27916047
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atorvastatin (intensive group)
Study: 22525762
Drug: DDEA 2.32%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDEA 2.32% gel bid
Study: 22525762
Drug: DDEA 2.32%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDEA 2.32% gel tid
Study: 22525762
Drug: DDEA 2.32%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDEA 2.32% gel bid or tid
Study: 22525762
Drug: DDEA 2.32%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDEA 2.32% gel
Study: 12009244
Drug: VIP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP regimen (vindesine 3 mg/m² on days 1 and 8, ifosfamide 1300 mg/m² on days 1-5, cisplatin 20 mg/m² on days 1-5)
Study: 12009244
Drug: VP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VP regimen (vindesine and cisplatin with the same dose and schedule as VIP)
Study: 10047931
Drug: Rimantadine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimantadine at doses of 100 to 300 mg/d
Study: 31081862
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic blood pressure target of 110-139 mm Hg)
Study: 31081862
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (systolic blood pressure target of 140-179 mm Hg)